Category Archives: ADCetris

An Advertising Guru In Brazil

José Borghi, founder of a renowned Mullen Lowe agency. Due to his expertise, in-depth analysis skills and a keen eye on the client’s request, he considered as the most influential advertisers in whole Brazil. The presence of Borghi among the most creative advertising personality in whole Brazil was because of many reasons, including the competence of launching diverse campaigns.

He is also the inventor of repercussion campaigns such as Mammals of Parmalat. In MoP, kids wear outfits of stuffed animals and sang memorable jingles. In his early hood, in was not sure which career to shoot. While still in high school, he went to the Castro Neves Theater to see the performance of his sister. From there, Borghi already knew what career should he aim for, but he wouldn’t predict that in he will win Cannes Lion award one day.

José Henrique Borghi, born at Presidente Prudente earned his professional education from PUC-Campinas in Propaganda and Advertising. His first professional was in the year 1989 at an advertisement agency Standart Ogilvy and by working in many companies, he becomes Entrepreneur by inaugurating his firm Mullen Lowe. This agency has gained and grown even more evidence in the local and global market. By having a merger between the Mullen group and Lowe & Partners, the agency has become Mullen Lowe. An advertiser who is also a Marathon runner trusted in his ability, and he turned out to be the reliable and one of the trusted names in the advertising industry.

The awards that he earned in his extensive career as one of the most renowned and trusted advertising tycoons are not limited to very few. He honored with seven London Festival statuettes awards; fourteen for Cannes Festival lions, ten awards from The One Show, 10 for The New York Festival and his agency also accredited as the Brazilian Advertising Festival.

Clay Siegall builds biotech empire from scratch

Clay Siegall first became aware of the brutality of chemotherapy while still in college. He decided that he would like to dedicate himself to finding new ways to treat and maybe someday cure the disease, which kills more people than anything else in the United States.


After working for a decade in various capacities with the National Cancer Institute as well as Bristol Meyers Squibb, Siegall founded Seattle Genetics, a biotech firm dedicated to the development of antibody drug conjugates. Antibody drug conjugates are a type of cancer treatment that has the same primary effects of chemotherapy but without the horrible side effects.

When he founded his company, Siegall had just a skeleton staff and a few million dollars in venture capital. But over the next three years, he built the company into a respectable research firm, with multiple patents to its credit. In 2001, Siegall led Seattle Genetics’ IPO. It raised over $1 billion. This was one of the most successful IPOs in biotech history and quickly propelled Seattle Genetics to the upper echelons of cutting-edge cancer treatment innovators.


Over the next decade, the company developed many of its own drugs. In 2011, it received FDA approval for its first patient-ready drug, ADCetris. ADCetris is an antibody drug conjugate approved for use in certain cases of refractory non-Hodgkin lymphoma. This drug has saved hundreds of lives and incalculable suffering by sparing its users from the horrors of chemotherapy.

Seattle Genetics currently has twelve drugs in the development pipeline and many more that are leased out to other firms for production and further development. It has developed a large number of proprietary processes for the synthesis of antibody drug conjugates as well as many of its own biochemical processes. Today, Seattle Genetics ranks among the most prominent players in the alternative drug cancer research space.

It expects at least five more drugs to receive FDA approval in the next few years. This will solidify its competitive position and free up more resources for its continued development of innovative cancer treatments. It is hoped by Dr. Clay  Siegall that someday soon, one of those drugs may even include a cure.